[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research progress onneoadjuvant therapy in stage ⅢA-N2 non-small cell lung cancer
Sun Xin1, Men Yu2, Hui Zhouguang2
1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100021, China 2Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100021, China
Abstract ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy,radiotherapy,target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities.
Sun Xin,Men Yu,Hui Zhouguang. Research progress onneoadjuvant therapy in stage ⅢA-N2 non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(1): 61-64.
Sun Xin,Men Yu,Hui Zhouguang. Research progress onneoadjuvant therapy in stage ⅢA-N2 non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(1): 61-64.
[1]Depierre A,Milleron B,Moro-Sibilot D,et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage Ⅰ(except TN1N0),Ⅱ,and ⅢA non-small-cell lung cancer[J]. J Clin Oncol,2002,20(1):247-253. DOI:10.1200/JCO.2002.20.1.247.
[2]Nagai K,Tsuchiya R,Mori T,et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stageⅢA N2 non-small cell lung cancer (JCOG 9209)[J]. J Thorac Cardiovasc Surg,2003,125(2):254-260. DOI:10.1067/mtc.2003.15.
[3]Rosell R,Lopez-Cabrerizo MP,Astudillo J,et al. Preoperative chemotherapy for stage ⅢA non-small cell lung cancer[J]. Curr Opin Oncol,1997,9(2):149-155.
[4]Roth JA,Fossella F,Komaki R,et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage ⅢA non-small-cell lung cancer[J]. J Natl Cancer Inst,1994,86(9):673-680.
[5]Burdett RL,Tierney JF,Auperin A,et al. Preoperative chemotherapy for non-small-cell lung cancer:a systematic review and meta-analysis of individual participant data[J]. Lancet,2014,383(9928):1561-1571. DOI:10.1016/s0140-6736(13)62159-5.
[6]Berghmans T,Paesmans M,Meert AP,et al. Survival improvement in resectable non-small cell lung cancer with (neo) adjuvant chemotherapy:results of a meta-analysis of the literature[J]. Lung Cancer,2005,49(1):13-23. DOI:10.1016/j.lungcan.2005.01.002.
[7]Pisters KM,Evans WK,Azzoli CG,et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages Ⅰ-ⅢA resectable non small-cell lung cancer guideline[J]. J Clin Oncol,2007,25(34):5506-5518. DOI:10.1200/jco.2007.14.1226.
[8]Burdett S,Stewart LA,Rydzewska L,et al. A systematic review and meta-analysis of the literature:chemotherapy and surgery versus surgery alone in non-small cell lung cancer[J]. J Thorac Oncol,2006,1(7):611-621. DOI:10.1016/S1556-0864(15)30371-3.
[9]Pignon JP,Tribodet H,Scagliotti GV,et al. Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Group[J]. J Clin Oncol,2008,26(21):3552-3559. DOI:10.1200/jco.2007.13.9030.
[10]Wu YL,Yang XN,Zhong W,et al. Multi-centre randomized controlled study comparing adjuvant vs. neo-adjuvant chemotherapy with docetaxel plus carboplatin in resectable stage ⅠB to ⅢA NSCLC:final results of CSLC0501[J]. Ann Oncol,2016,27(Suppl6):11780-11780.
[11]Johnstone DW,Byhardt RW,Ettinger D,et al.Phase Ⅲ study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01[J].Int J Radiat Oncol Biol Phys,2002,54(2):365-369.DOI:10.1016/S0360-3016(02)02943-7.
[12]Stephens RJ,Girling DJ,Hopwood P,et al. A randomised controlled trial of pre-operative chemotherapy followed,if feasible,by resection versus radiotherapy in patients with inoperable stage T3,N1,M0 or T1-3,N2,M0 non-small cell lung cancer[J]. Lung Cancer,2005,49(3):395-400. DOI:10.1016/j.lungcan.2005.04.001.
[13]van Meerbeeck JP,Kramer GW,Van Schil PE,et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage ⅢA-N2 non-small-cell lung cancer[J]. J Natl Cancer Inst,2007,99(6):442-450. DOI:10.1093/jnci/djk093.
[14]Katakami N,Tada H,Mitsudomi T,et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage ⅢA nonsmall cell lung cancer (WJTOG9903)[J]. Cancer,2012,118(24):6126-6135. DOI:10.1002/cncr.26689.
[15]Girard N,Mornex F,Douillard JY,et al. Is neoadjuvant chemoradiotherapy a feasible strategy for stage ⅢA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase Ⅱ trial[J]. Lung Cancer,2010,69(1):86-93. DOI:10.1016/j.lungcan.2009.10.003.
[16]Shah AA,Berry MF,Tzao C,et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage ⅢA lung cancer[J]. Ann Thorac Surg,2012,93(6):1807-1812. DOI:10.1016/j.athoracsur.2012.03.018.
[17]Pless M,Stupp R,Ris HB,et al. Induction chemoradiation in stage ⅢA/N2 non-small-cell lung cancer:a phase 3 randomised trial[J]. Lancet,2015,386(9998):1049-1056. DOI:10.1016/s0140-6736(15)60294-x.
[18]Xu YP,Li B,Xu XL,et al. Is There a Survival benefit in patients with stage ⅢA(N2) non-small cell lung cancer receiving neoadjuvant chemotherapy and/or radiotherapy prior to surgical resection:asystematic review and Meta-analysis[J]. Medicine (Baltimore),2015,94(23):e879. DOI:10.1097/md.0000000000000879.
[19]Higgins K,Chino JP,Marks LB,et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage Ⅲ(N2) non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2009,75(5):1462-1467. DOI:10.1016/j.ijrobp.2009.01.069.
[20]Albain KS,Rusch VW,Crowley JJ,et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages ⅢA(N2) and ⅢB non-small-cell lung cancer:mature results of Southwest Oncology Group phase Ⅱ study 8805[J]. J Clin Oncol,1995,13(8):1880-1892.
[21]Katakami N,Okazaki M,Nishiuchi S,et al. Induction chemoradiotherapy for advanced stage Ⅲ non-small cell lung cancer:long-term follow-up in 42 patients[J]. Lung Cancer,1998,22(2):127-137.
[22]Thomas M,Rube C,Semik M,et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage Ⅲ non-small-cell lung cancer[J]. J Clin Oncol,1999,17(4):1185.
[23]Albain KS,Swann RS,Rusch VW,et al. Radiotherapy plus chemotherapy with or without surgical resection for stage Ⅲ non-small-cell lung cancer:a phase Ⅲ randomised controlled trial[J]. Lancet,2009,374(9687):379-386. DOI:10.1016/s0140-6736(09)60737-6.
[24]Eberhardt WE,Pottgen C,Gauler TC,et al. Phase Ⅲstudy of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage ⅢA(N2) and selected ⅢBnon-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE)[J]. J Clin Oncol,2015,33(35):4194-4201. DOI:10.1200/jco.2015.62.6812.
[25]Zhong W,Yang X,Yan H,et al. Phase Ⅱ study of biomarker-guided neoadjuvant treatment strategy for ⅢA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status[J]. J Hematol Oncol,2015,8(1):54. DOI:10.1186/s13045-015-0151-3.
[26]Forde PM,Chaft JE,Smith KN,et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med,2018,378(21):1976-1986. DOI:10.1056/NEJMoa1716078.
2020, Vol. 29 
